Virupaksha Organics completes Vivin Drugs buyout
By Abha Lohia ·
- Virupaksha Organics is a Hyderabad drug-ingredient maker preparing for a public listing with a planned ₹740 crore issue
- It has finished buying bankrupt Vivin Drugs and Vivin Laboratories under a ₹104 crore insolvency resolution plan
- The deal adds anti-viral ingredient capacity and is the company's third acquisition before its market debut
What happened
- Virupaksha closed the ₹104 crore Vivin purchase.
- The tribunal cleared the plan in August.
- Vivin Laboratories will merge into Vivin Drugs.
Why it matters
- It widens the product range in anti-viral ingredients.
- It adds manufacturing capacity ahead of the IPO.
- Lenders backed the plan with a very large majority.
The business
- Virupaksha makes active pharmaceutical ingredients (the core drug chemicals).
- It is based in Hyderabad.
In numbers
₹740 CrPlanned IPO size · 2026
What happens next
- Public issue of about ₹740 crore is planned.
Same day
- AV
AITMC Ventures · IPO · 6 October 2026AITMC files updated IPO document for fresh issue - BA
Beyond Appliances · Funding · 6 October 2026 · ₹110 CrBeyond Appliances raises ₹110 crore Series B - BL
Blinkit · Policy · 6 October 2026FDA cancels registration of Blinkit Vile Parle unit
- CU
CureMeAbroad · Funding · 6 October 2026 · $1.1MCureMeAbroad raises $1.1M pre-seed - CU
CurvetAI · Funding · 6 October 2026 · ₹6 CrCurvetAI raises ₹6 crore pre-seed led by Merak Ventures - FY
FYDY · Funding · 6 October 2026 · $12MFYDY in talks for $12M funding
Is this Virupaksha Organics? Get your “Featured on StopDown” badge →